Boston Scientific Receives CE Mark For Eluvia™ Drug-Eluting Vascular Stent and Announces Initiation of New Clinical Trial
Boston Scientific | February 22, 2016
Boston Scientific (NYSE: BSX) today announced that the Eluvia™ Drug-Eluting Vascular Stent System has received CE Mark and is commencing commercialization immediately in the European Union and other countries where CE Mark is recognized.